The aptly named Exoskeleton Assisted-Walking in Persons with SCI: Impact on Quality of Life study is slated to enroll 160 patients at 6 participating VA Medical Centers across California, Florida, Massachusetts, Texas and Virginia.
“This VA clinical trial is groundbreaking in both its purpose and scope, and will undoubtedly provide a wealth of quality research data to the department’s already impressive research. ReWalk is glad to provide our technology to enable this critical national study,” CEO Larry Jasinski said in a press release.
ReWalk Robotics said the VA plans to initiate the study in October this year.
In January, ReWalk Robotics said the VA awarded a delivery order to the Veterans Healthcare Supply Solutions for its Robotic Exoskeleton systems to use in the upcoming 4-year trial.
The company said it has already shipped 6 of those systems for the trial.
In December, ReWalk saw shares jump after the U.S. Department of Veterans Affairs issued a policy to evaluate, train and procure its personal exoskeleton systems for all qualifying veterans in the U.S. ReWalk stocks rose over 32% in day trading after the announcement.
ReWalk develops and produces exoskeletons designed to restore self-initiated walking for patients with spinal cord injuries. The personal system is battery-powered and features an array of sensors and motors that detect the wearer’s movement and assist in standing up, sitting down and upright walking.